# Altered expressions of CXCR4 and CD26 on T-helper lymphocytes in hereditary hemorrhagic telangiectasia

Alexandre Guilhem, Pierre Portalès, Sophie Dupuis-Girod, Sophie Rivière, Thierry Vincent

<figure><img src="image_1.png" /></figure>

## To cite this version:

Alexandre Guilhem, Pierre Portalès, Sophie Dupuis-Girod, Sophie Rivière, Thierry Vincent. Altered expressions of CXCR4 and CD26 on T-helper lymphocytes in hereditary hemorrhagic telangiectasia. Orphanet Journal of Rare Diseases, 2021, 16 (1), pp.511. 10.1186/s13023-021-02139-y. hal-03635454

HAL Id: hal-03635454

https://hal.umontpellier.fr/hal-03635454

Submitted on 8 Apr 2022

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
RESEARCH

Open Access

<figure><img src="image_3.png" /></figure>

Check for
updates

# Altered expressions of CXCR4 and CD26 on T-helper lymphocytes in hereditary hemorrhagic telangiectasia

Alexandre Guilhem<fnref n="1" />* ID, Pierre Portalès², Sophie Dupuis-Girod³, Sophie Rivière<fnref n="1" /> and Thierry Vincent²

## Abstract

**Background:** Hereditary hemorrhagic telangiectasia (HHT) is a rare genetic disease characterized by a deregulated neo-angiogenesis. Besides a mainly vascular phenotype (muco-cutaneous telangiectases, arteriovenous malformations), a specific risk of infection is suggested by case series of severe and atypical infections as well as by reports of decreased T and natural killer (NK) lymphocyte counts. As some evidence supports a dysregulation of the CXCR4/CXCL12 chemotactic axis of HHT endothelial cells, we hypothesized that a similar phenomenon could occur on lymphocytes.

**Methods:** Eighteen HHT patients with history of severe infection (HSI) were matched in age and sex with 18 HHT without HSI and 18 healthy control subjects (HC). We assessed the cell count and the surface expression of CXCR4 and CD26 (CXCL12 inactivating peptidase) of circulating T-helper and T-cytotoxic lymphocytes (including naive, memory and activated subsets) and NK cells.

**Results:** The overall HHT group of 36 patients exhibited a reduction of circulating T-helper lymphocytes compared to HC (median: 517 vs. 1026 cells/mm³, *p* < 0.0001), correlated with age (r = −0.46, *p* = 0.005), requirement of intra-venous iron or blood transfusions (median: 291 vs. 627 cells/mm³, *p* = 0.03) and CXCR4 surface expression (r = 0.353, *p* = 0.0345). CXCR4 and CD26 membrane expression were both decreased on HHT T-helper lymphocytes (median MFI ratio: 4.49 vs. 5.74 for CXCR4 and 3.21 vs. 4.33 for CD26, *p* = 0.03 and 0.0018 respectively) with an unchanged CXCR4/CD26 ratio. The HHT group with HSI had a higher CXCR4/CD26 ratio on the total T-lymphocyte population, as well as on the T-helper population and its naive subset (median on naive T-helper cells: 2.34 vs. 1.32, *p* = 0.0002).

**Conclusions:** Our findings support a dysregulation of the CXCL12/CXCR4 chemotaxis of T-helper lymphocytes in HHT patients, potentially linked to their T-helper lymphopenia and susceptibility to infection.

**Keywords:** Hereditary hemorrhagic telangiectasia, T-helper lymphocytes, CXCR4, CD26, Susceptibility to infection

## Background

Hereditary hemorrhagic telangiectasia (HHT) is a vascular genetic disease with an estimated prevalence of 1 in 5000–8000. Mutations in several genes of the BMP9/BMP10 signaling pathway (ENG and ACVRL1 mainly)

result in a deregulated neo-angiogenesis. The inheritance pattern is autosomal dominant, and the penetrance is usually complete after 50 years. The clinical presentation includes spontaneous and recurrent epistaxis (frequently complicated by iron-deficiency anemia), muco-cutaneous telangiectases (face, oral cavity, hands), and less frequently visceral arteriovenous malformations (AVM) of the lungs, the liver, the digestive tract or the central nervous system [1].

<footnote>*Correspondence: alexandre.guilhem@gmail.com</footnote>

<footnote n="1">¹ CHU de Montpellier, Médecine interne et maladies multi-organiques de l'adulte, Hôpital Saint Eloi, Montpellier, France
Full list of author information is available at the end of the article</footnote>
Besides this vascular phenotype, some studies reported atypical and severe infections, including cerebral abscesses and musculoskeletal infections, affecting up to 15% of the patients. The actual prevalence and clinical significance of these manifestations have yet to be confirmed by large prospective studies comparing this risk with that of the general population. The most specific events are cerebral abscesses with anaerobic bacteria, generally attributed to septic emboli allowed by right-to-left cardiac shunting due to pulmonary AVM. Patients also seem to be concerned more frequently by musculoskeletal infections involving *Staphylococcus aureus*, which may be associated with bacteremia provoked by prolonged nose packing or/and lesions of the nasal mucosa [2, 3]. In addition to these mechanical factors, innate immunity is suspected to be altered in HHT: functional deficits of neutrophils and monocytes/macrophages (phagocytosis, oxidative burst, NETs formation) have been reported in humans [4, 5] and mice [6], but their exact clinical meaningfulness as well as their underlying mechanism are still to be elucidated. Intriguingly, immunological studies have highlighted a T and NK lymphopenia predominant on naive T-helper cells [5, 7]. Although very low lymphocyte counts were observed in some patients, no clear association with infectious risk has been established to date.

The chemokine CXCL12 (formerly named SDF1) and its cellular receptor CXCR4 constitute a powerful chemotactic axis for many cell types. It is in particular used

by T lymphocytes for trafficking and homeostasis [8]. CD26 is a known CXCL12 inactivating peptidase, functionally associated with CXCR4 on T lymphocytes [9]. Besides this enzymatic activity, CD26 acts as a co-stimulatory molecule during T-lymphocyte activation [10, 11]. In endothelial cells, CXCL12 and CXCR4 expressions are regulated by BMP9 in an endoglin-dependent manner: BMP9 and hypoxia are additive inducers of CXCL12 release while surface CXCR4 is downregulated [12]. Imbalance of this chemotactic axis has also been described on peripheral blood mononuclear cells (MNCs) in one study. The migration capacities of HHT MNCs towards a CXCL12 gradient were reduced as a result of a CD26 hyper-expression, which was overcoming elevated surface levels of CXCR4 [13].

Here, we describe the CXCR4 and CD26 expression levels in different lymphocyte subsets of HHT patients with history of severe infection (HSI), in comparison with HHT patients without HSI and with healthy control subjects (HC) matched in age and sex. We provide several elements supporting an alteration in the CXCL12/CXCR4 axis on T-helper lymphocytes in HHT patients, possibly related to their specific infectious risk and T-helper lymphopenia.

## Results

### Demographics and clinical characteristics

According to the schematic timeline shown in Fig. 1, 18 HHT patients with at least one history of severe infection

<figure><img src="image_4.png" /></figure>
were enrolled between January and October 2012, concomitantly with 18 HHT patients without any history of severe infection and with 18 HC. The main characteristics are detailed in Table 1. With a median age of 60 years and a male predominance, the HHT group was well-balanced in term of causative mutation and epistaxis intensity during the last month before inclusion. One third of the group had at least one pulmonary AVM. A majority of patients (56%) required intravenous (IV) treatments for iron-deficient anemia (IV iron or blood transfusion), and 4 (11%) were under bevacizumab.

Thirty episodes of severe infection were identified in the medical history of 18 HHT patients (1.67 episodes/patient): 7 cerebral abscesses, 8 osteoarticular infections (including 6 cases of spondylodiscitis), 5 cutaneous or soft tissue infections, 3 cases of bacteremia, 2 cases of pneumonia (including one with pulmonary abscess), 2 cases of pyelonephritis, 1 case of prostatitis, 1 case of sigmoiditis and 1 case of bartholinitis. The infectious agents were: *Staphylococcus aureus* in 10 cases, anaerobic bacteria from the oral cavity in 9 cases, 4 cases of *Enterobacteriaceae*, and 2 anaerobic bacteria from the digestive tract (no microbe identified in 5 cases).

The median age at the first episode of infection was 46 years (min-max: 21–67 years). The median duration between the last episode of infection and the inclusion in the study was 2.3 years (min-max: 1–16 years). Two episodes were classified as septic shock and one as sepsis according to the Sepsis-3 consensus definitions [14].

## Surface expression of CXCR4 and CD26 on T and NK lymphocytes

By comparing all the 36 HHT patients (with or without HSI) to the 18 HC in Fig. 2, we observed a significant decrease in total T-lymphocyte count in the HHT group (median: 833 vs. 1436 cells/mm<fnref n="3" />, *p* = 0.0009), linked to a reduction of the T-helper sub-population (median: 517 vs. 1026 cells/mm<fnref n="3" />, *p* < 0.0001) with a more pronounced impact on the naive cells (median: 254 vs. 577 cells/mm<fnref n="3" />, *p* < 0.0001). The NK lymphocytes were equally diminished (median: 184 vs. 284 cells/mm<fnref n="3" />, *p* = 0.048).

CXCR4 and CD26 had both a lower mean fluorescence intensity (MFI) on T-helper lymphocytes in the HHT group (median MFI ratio: 4.49 vs. 5.74 for CXCR4 and

<table><caption>**Table 1** Demographics and clinical characteristics of the subjects</caption><thead><tr><th></th><th>HHT (n = 36)</th><th>Controls (n = 18)</th><th></th></tr></thead><tbody><tr><td>Age (mean, SD)</td><td>60.2 (10.4)</td><td>59.7 (10.2)</td><td>p = 0.868</td></tr><tr><td>Sex (males, %)</td><td>26 (72%)</td><td>13 (72%)</td><td>p = 1</td></tr><tr><td>History of severe infection (n, %)</td><td>18 (50%)</td><td>0 (0%)</td><td></td></tr><tr><td>Mutation (n, %):</td><td></td><td></td><td></td></tr><tr><td>ENG</td><td>18 (50%)</td><td></td><td></td></tr><tr><td>ACVRL1</td><td>16 (44%)</td><td></td><td></td></tr><tr><td>SMAD4</td><td>0 (0%)</td><td></td><td></td></tr><tr><td>Not identified</td><td>2 (6%)</td><td></td><td></td></tr><tr><td>Visible telangiectases (median, min-max)</td><td>70 (0–242)</td><td></td><td></td></tr><tr><td>Epistaxis frequency<fnref n="1" /> (n, %)</td><td></td><td></td><td></td></tr><tr><td>Daily</td><td>13 (36%)</td><td></td><td></td></tr><tr><td>Weekly</td><td>13 (36%)</td><td></td><td></td></tr><tr><td>Monthly or more rarely</td><td>10 (28%)</td><td></td><td></td></tr><tr><td>Arteriovenous malformations (n, %<fnref n="2" />)</td><td></td><td></td><td></td></tr><tr><td>Lung<fnref n="3" /></td><td>12 (34%)</td><td></td><td></td></tr><tr><td>Digestive tract</td><td>19 (73%)</td><td></td><td></td></tr><tr><td>Liver</td><td>15 (44%)</td><td></td><td></td></tr><tr><td>Brain</td><td>6 (25%)</td><td></td><td></td></tr><tr><td>Treatment (n, %)</td><td></td><td></td><td></td></tr><tr><td>IV iron or blood transfusion (at least 5)</td><td>20 (56%)</td><td></td><td></td></tr><tr><td>Tranexamic acid</td><td>6 (17%)</td><td></td><td></td></tr><tr><td>Bevacizumab</td><td>4 (11%)</td><td></td><td></td></tr></tbody></table>

n: Number of patients

<footnote n="1">¹ During the last month before blood sampling</footnote>

<footnote n="2">² % of patients with a screening performed for the specified organ</footnote>

<footnote n="3">³ Only those large enough to be considered for treatment (usually diameter of the feeding artery > 3 mm)</footnote>
<figure><img src="image_5.png" /><figcaption>**Fig. 2** Lymphocyte subpopulations and CXCR4-CD26 surface expressions. In 36 HHT patients (black bar or dots) and 18 healthy control subjects (grey bar or dots) matched by age and sex: a absolute counts of T, B and NK lymphocytes, b absolute counts of T-helper lymphocytes (total, naive, memory and activated), c absolute counts of T-cytotoxic lymphocytes (total, naive, memory and activated), d CXCR4 expression on T-helper, T-cytotoxic and NK lymphocytes, e CD26 expression on T-helper, T-cytotoxic and NK lymphocytes, f ratio of CXCR4/CD26 expressions on T-helper, T-cytotoxic and NK lymphocytes, g CXCR4 expression on naive, memory and activated T-helper lymphocytes, h CD26 expression on naive, memory and activated T-helper lymphocytes, i ratio of CXCR4/CD26 expressions on naive, memory and activated T-helper lymphocytes, j correlation between absolute counts of T-helper lymphocytes and their expression of CXCR4 in the HHT group, k correlation between absolute counts of T-helper lymphocytes and their expression of CD26 in the HHT group, l correlation between CXCR4 and CD26 surface expression on T-helper lymphocytes in the HHT group, m correlation between absolute counts of T-helper lymphocytes and their expression of CXCR4 in the control group, n correlation between absolute counts of T-helper lymphocytes and their expression of CD26 in the control group, o correlation between CXCR4 and CD26 surface expression on T-helper lymphocytes in the control group. MFI: mean fluorescence intensity. Results are presented in bar charts with median and interquartile ranges (for comparisons) or individual values with Spearman r coefficients (for correlations). Comparisons between groups were performed using the Mann-Whitney U-test. Correlations between variables were performed using the Spearman's rank test. *P*-values are shown</figcaption></figure>

3.21 vs. 4.33 for CD26, *p*=0.03 and 0.0018 respectively). Decreased membrane expression was also significant for CD26 on naive and memory subsets (median MFI ratio: 4.96 vs. 7.26 for naive and 2.48 vs. 3.08 for memory, *p*=0.01 and 0.0022 respectively). T-cytotoxic lymphocytes and their subsets exhibited no significant difference in CXCR4 and CD26 MFI ratio (data not shown). The CXCR4/CD26 ratio was not altered in the NK and the different T lymphocyte subsets.

A weak but significant positive correlation was observed in the HHT group between the surface expression of CXCR4 on T-helper lymphocytes and their absolute count (r=0.353, *p*=0.0345). A stronger positive correlation was present between the CXCR4 and the CD26 expression on this subset (r=0.561, *p*=0.0004). These two observations were not found in the HC group.

The influence of the main HHT characteristics on T-helper count, the CXCR4 MFI ratio and the CD26 MFI ratio was tested in Fig. 3. Patients receiving IV iron or blood transfusions showed a significant reduction of

T-helper count (median: 291 vs. 627 cells/mm³, *p*=0.03). The T-helper count was also correlated with the age of the patients (r=-0.46, *p*=0.005). The decrease of the CD26 MFI ratio followed the same tendencies for age and IV treatment of anemia, without reaching the statistical threshold. Another positive tendency was found between CXCR4 MFI ratio and hemoglobin level. We did not observe any differences between ENG and AVCRL1-mutated patients.

A multivariate analysis was carried out to assess the independence of the correlations between T-helper absolute count, age, requirement of IV treatment for iron-deficiency anemia and CXCR4 MFI ratio on T-helper cells, in the HHT group. The results of the multivariable linear regression are shown in Additional file 1: Table S1. Only the age of the HHT patients remained significantly related to the T-helper cell count (*p*=0.042).
<figure><img src="image_6.png" /><figcaption>**Fig. 3** Influence of main HHT characteristics on T-helper count and their CXCR4 and CD26 surface expressions. Among the 36 subjects of the HHT group, comparisons of the T-helper count (a), the CXCR4 MFI ratio (b) and the CD26 MFI ratio (c) according to sex (male: 26, female: 10), mutations (ENG: 18, ACVRL1: 16), frequency of epistaxis (daily: 13, weekly: 13, month or less: 10), pulmonary AVM (with: 12, without: 23), digestive AVM (with: 19, without: 7), hepatic AVM (with: 15, without: 19), IV iron or transfusion (with: 20, without: 16). Correlations between T-helper count, CXCR4 expression, CD26 expression and age (d), number of telangiectases per patient (e), hemoglobin (f), ferritin (g). MFI: mean fluorescence intensity, Ep.: epistaxis, pAVM: pulmonary arteriovenous malformation, dAVM: digestive arteriovenous malformation, hAVM: hepatic arteriovenous malformation. Results are presented in bar charts with median and interquartile ranges (for comparisons) or individual values with Spearman r coefficient (for correlations). Comparisons between groups were performed using the Kruskal–Wallis or the Mann–Whitney U-test. Correlations between variables were performed using the Spearman's rank test. *P*-values are shown</figcaption></figure>

## Clinical and biological parameters associated with history of severe infection

By comparing the clinical characteristics of the 18 HHT patients with HSI to the 18 without HSI (Table 2), we observed a higher frequency of pulmonary AVM (50% vs. 18%, *p* = 0.044). The proportions of ENG and ACVRL1 mutated patients were not different between groups. The comparison of the immunological parameters revealed a higher expression of CXCR4 on naive T-helper lymphocytes (median MFI ratio: 9.65 vs. 7.01, *p* = 0.03) and a lower expression of CD26 on naive T-helper lymphocytes (median MFI ratio: 4.59 vs. 5.73, *p* = 0.03) in the HSI group. Consequently the CXCR4/CD26 ratio of this subset was higher in the

HSI group (median: 2.34 vs. 1.32, *p* = 0.0002). Similarly, we observed in the HSI group an increase of the CXCR4/CD26 ratio on the T-helper (median: 1.58 vs. 1.37, *p* = 0.01) and the total T lymphocyte populations (median: 1.63 vs. 1.32, *p* = 0.04). This ratio was not significantly different between patients with and without pulmonary AVM (median: 2.15 vs. 1.51, *p* = 0.71).

## Discussion

CXCR4 is the G protein-coupled receptor of the pleiotropic chemokine CXCL12. This chemotactic axis is fundamental during organogenesis, angiogenesis and homeostasis of the hematopoietic and immune systems.
<table><caption>**Table 2** Comparisons of clinical and biological characteristics (a) and lymphocyte parameters (b) between HHT patients with or without history of severe infection</caption><thead><tr><th></th><th>HHT with HSI</th><th>HHT without HSI</th><th>p</th></tr></thead><tbody><tr><td colspan="4">(a) Clinical and biological characteristics</td></tr><tr><td>Age (mean, SD)</td><td>60.0 (10.3)</td><td>60.4 (10.5)</td><td>0.91</td></tr><tr><td>Sex (male, %)</td><td>13 (72%)</td><td>13 (72%)</td><td>1</td></tr><tr><td>Mutation (n, %)<sup>1</sup></td><td></td><td></td><td></td></tr><tr><td>- ENG</td><td>11 (61%)</td><td>7 (39%)</td><td>0.49</td></tr><tr><td>- ACVRL1</td><td>7 (39%)</td><td>9 (50%)</td><td></td></tr><tr><td>Epistaxis frequency (n, %)</td><td></td><td></td><td></td></tr><tr><td>- Daily</td><td>6 (34%)</td><td>7 (39%)</td><td>0.56</td></tr><tr><td>- Weekly</td><td>8 (44%)</td><td>5 (28%)</td><td></td></tr><tr><td>- Monthly or more rarely</td><td>4 (22%)</td><td>6 (34%)</td><td></td></tr><tr><td>Visible telangiectases (median, min-max)</td><td>58 (0-242)</td><td>90 (0-200)</td><td>0.39</td></tr><tr><td>Arteriovenous malformations (n, %<sup>2</sup>)</td><td></td><td></td><td></td></tr><tr><td>- Lung<sup>3</sup></td><td><strong>9 (50%)</strong></td><td><strong>3 (18%)</strong></td><td><strong>0.044</strong></td></tr><tr><td>- Digestive tract</td><td>7 (63%)</td><td>12 (80%)</td><td>0.35</td></tr><tr><td>- Liver</td><td>8 (44%)</td><td>7 (44%)</td><td>0.97</td></tr><tr><td>- Brain</td><td>5 (29%)</td><td>1 (14%)</td><td>0.78</td></tr><tr><td>Treatment (n, %)</td><td></td><td></td><td></td></tr><tr><td>- IV iron or blood transfusion (at least 5)</td><td>8 (44%)</td><td>12 (67%)</td><td>0.14</td></tr><tr><td>- Tranexamic acid</td><td>2 (11%)</td><td>4 (22%)</td><td>0.37</td></tr><tr><td>- Bevacizumab</td><td>1 (6%)</td><td>3 (17%)</td><td>0.29</td></tr><tr><td>Basic biological parameters (median, min-max):</td><td></td><td></td><td></td></tr><tr><td>Hemoglobin (g/l)</td><td>135 (80-188)</td><td>126 (78-157)</td><td>0.16</td></tr><tr><td>Platelets (G/l)</td><td>245 (178-388)</td><td>262 (236-488)</td><td>0.15</td></tr><tr><td>Leucocytes (G/l)</td><td>5.44 (3.00-8.92)</td><td>5.23 (3.02-10.23)</td><td>0.95</td></tr><tr><td>Neutrophils (G/l)</td><td>4.06 (1.73-7.65)</td><td>4.02 (1.94-8.19)</td><td>0.67</td></tr><tr><td>Lymphocytes (G/l)</td><td>0.92 (0.3-2.4)</td><td>1.02 (0.4-2.34)</td><td>0.89</td></tr><tr><td>C reactive protein (mg/l)</td><td>2.63 (0.2-8.4)</td><td>1.85 (0.2-7.3)</td><td>0.63</td></tr><tr><td>Ferritin (ng/ml)</td><td>76 (9-158)</td><td>57 (7-221)</td><td>0.43</td></tr><tr><td>Creatinine clearance (MDRD, ml/min)</td><td>85 (36-107)</td><td>86.5 (42-140)</td><td>0.52</td></tr><tr><td>Immunoglobulin G (g/l)</td><td>8.73 (2.7-16.8)</td><td>9.16 (3.16-16.9)</td><td>0.87</td></tr><tr><td>Immunoglobulin A (g/l)</td><td>2.10 (1.04-4.3)</td><td>2.23 (1.07-4.06)</td><td>0.64</td></tr><tr><td>Immunoglobulin M (g/l)</td><td>0.69 (0.36-1.79)</td><td>0.72 (0.19-1.9)</td><td>0.97</td></tr><tr><td colspan="4">(b) Lymphocyte parameters (median, min-max)</td></tr><tr><td>T lymphocytes (cells/mm3)</td><td>841 (219-2116)</td><td>829 (214-1831)</td><td>0.44</td></tr><tr><td>T-helper lymphocytes (cells/mm3)</td><td>517 (96-1499)</td><td>550 (123-1061)</td><td>0.83</td></tr><tr><td>T-cytotoxic lymphocytes (cells/mm3)</td><td>339 (90-848)</td><td>187 (51-1110)</td><td>0.12</td></tr><tr><td>NK lymphocytes (cells/mm3)</td><td>211 (12-989)</td><td>170 (55-946)</td><td>0.64</td></tr><tr><td>Naive T-helper lymphocytes (cells/mm3)</td><td>273 (8-978)</td><td>201 (14-630)</td><td>0.55</td></tr><tr><td>Memory T-helper lymphocytes (cells/mm3)</td><td>236 (79-519)</td><td>280 (109-798)</td><td>0.60</td></tr><tr><td>Activated T-helper lymphocytes (cells/mm3)</td><td>59 (19-151)</td><td>58 (30-215)</td><td>0.78</td></tr><tr><td>CXCR4 MFI on T lymphocytes</td><td>3.87 (2.17-18.36)</td><td>3.74 (2.20-14.30)</td><td>0.80</td></tr><tr><td>CXCR4 MFI on T-helper lymphocytes</td><td>4.80 (2.91-14.00)</td><td>4.17 (2.40-8.20)</td><td>0.48</td></tr><tr><td>CXCR4 MFI on Naive T-helper lymphocytes</td><td><strong>9.65 (4.48-35.00)</strong></td><td><strong>7.01 (3.34-14.20)</strong></td><td><strong>0.03</strong></td></tr><tr><td>CXCR4 MFI on memory T-helper lymphocytes</td><td>3.06 (2.28-9.79)</td><td>3.33 (1.91-6.00)</td><td>0.64</td></tr><tr><td>CXCR4 MFI on activated T-helper lymphocytes</td><td>2.40 (1.71-8.15)</td><td>2.49 (1.63-4.00)</td><td>0.97</td></tr><tr><td>CD26 MFI on T lymphocytes</td><td>2.71 (1.41-5.13)</td><td>2.90 (2.21-6.54)</td><td>0.13</td></tr><tr><td>CD26 MFI on T-helper lymphocytes</td><td>3.01 (1.72-5.75)</td><td>3.26 (2.17-6.92)</td><td>0.19</td></tr><tr><td>CD26 MFI on naive T-helper lymphocytes</td><td><strong>4.59 (1.65-9.33)</strong></td><td><strong>5.73 (4.17-14.1)</strong></td><td><strong>0.03</strong></td></tr></tbody></table>
<table><caption>**Table 2** (continued)</caption><thead><tr><th></th><th>HHT with HSI</th><th>HHT without HSI</th><th>p</th></tr></thead><tbody><tr><td>CD26 MFI on memory T-helper lymphocytes</td><td>2.27 (1.58–3.48)</td><td>2.58 (2.00–5.08)</td><td>0.09</td></tr><tr><td>CD26 MFI on activated T-helper lymphocytes</td><td>1.63 (1.32–2.95)</td><td>1.57 (1.13–2.77)</td><td>0.29</td></tr><tr><td>CXCR4/CD26 ratio on T lymphocytes</td><td><strong>1.63 (0.52–5.45)</strong></td><td><strong>1.32 (0.45–4.38)</strong></td><td><strong>0.04</strong></td></tr><tr><td>CXCR4/CD26 ratio on T-helper lymphocytes</td><td><strong>1.58 (0.86–3.41)</strong></td><td><strong>1.37 (0.62–2.91)</strong></td><td><strong>0.01</strong></td></tr><tr><td>CXCR4/CD26 ratio on naive T-helper lymphocytes</td><td><strong>2.34 (0.87–5.68)</strong></td><td><strong>1.32 (0.51–3.01)</strong></td><td><strong>0.0002</strong></td></tr><tr><td>CXCR4/CD26 ratio on memory T-helper lymphocytes</td><td>1.38 (0.79–2.82)</td><td>1.39 (0.71–2.50)</td><td>0.25</td></tr><tr><td>CXCR4/CD26 ratio on activated T-helper lymphocytes</td><td>1.70 (0.70–2.96)</td><td>1.63 (0.99–2.65)</td><td>0.93</td></tr></tbody></table>

Statistically significant parameters are in bold

n: Number, HSI: History of severe infection, MFI: Mean fluorescence intensity

CXCL12 is highly expressed in bone marrow and is locally upregulated via HIF-1 after tissue injury to recruit stem cells and progenitors for damage repair [15, 16]. On T lymphocytes, CXCR4 is co-localized with CD26 (dipeptidylpeptidase IV), and both proteins are co-internationalized after activation by CXCL12. They form a functional unit participating in chemotaxis towards bone marrow and lymph nodes [9]. This pathway is involved in several diseases, including cancer [17], rheumatoid arthritis [18] and HIV [19]. Here, we report for the first time elements supporting a dysregulation of this axis on T lymphocytes in HHT.

As already published [5, 7], HHT is associated with a T and NK lymphopenia despite the absence of any comorbidities or treatment known to cause lymphopenia [20]. The decrease of the T-holders could be a consequence of a dysfunctional CXCL12/CXCR4 axis since we observed a weak but significant correlation between their CXCR4 surface expression and their absolute counts in the blood. This hypothesis is reinforced by the absence of such correlation in the control group. This phenomenon could be due to a direct effect of CXCL12 on naive T lymphocyte survival [21] or through disturbance in the T lymphocyte recirculation in lymph nodes and bone marrow, in which the CXCR4/CXCL12 axis is known to be important [8, 22]. The human aging of the immune system seems associated with a deregulation of CXCR4 expression on T-helper cell surface [23], but a such phenomenon is not observed in our study. The association between iron treatment and T-helper lymphopenia is more difficult to explain. It could be due to a direct effect of the treatment, maybe by increasing the oxygen reactive species in peripheral blood [24]. It also could be a consequence of the iron deficiency, which is known to induce a reduction in peripheral T cells and atrophy of the thymus [25]. As a third hypothesis, there could exist a confounding factor,

such as a subpopulation of patients with a more strongly activated neo-angiogenesis, impacting on both iron requirements and lymphocyte recruitment. Interventions studies are necessary to differentiate these hypotheses, especially since a link between the risk of cerebral abscess and IV iron loading has been reported [26].

We observed a correlated decrease in CXCR4 and CD26 expressions on T-helper lymphocytes of HHT patients without modification of the CXCR4/CD26 ratio. This is in apparent contradiction with a previous report of an over-expression of CXCR4 and CD26 on mononuclear cells with a decreased CXCR4/CD26 ratio associated with chemotactic impairment [13]. This discrepancy could be due to a different pattern of CXCR4 and CD26 surface expression between lymphocytes and monocytes. The monocytes have never been specifically studied in human HHT but are known to express these markers [27, 28]. Moreover, the previous study included only ENG-mutated patients. On T-helper lymphocytes, CXCR4 under-expression seems to be a central phenomenon in the idiopathic CD4 lymphopenia [29], but the infectious profiles are quite different. An alternative explanation could be a chronic elevation of the CXCL12 plasma level, described in severe infection [30, 31] and recently in HHT [32]. Such an elevation is known to lead to continuous CXCR4 and CD26 internalization as a desensitization process [9, 33]. The under-expression of CXCR4 on T-helper lymphocytes could delay and mitigate their antigenic response by limiting their migration and activation capacities [34–36]. The decrease of CXCR4 and CD26 surface expression seems to spare the T-cytotoxic and the NK lymphocytes. This observation is surprising since both molecules have documented biological roles on these cell types [11, 35, 37–39]. It could result from their

<footnote n="1">¹ No mutation identified for 2 patients, both in the HHT without HSI group</footnote>

<footnote n="2">² % of patients with a screening performed for the specified organ</footnote>

<footnote n="3">³ Only those large enough to be considered for treatment (diameter of the feeding artery > 3 mm)</footnote>
lower basal expression levels, limiting our ability to dis-
tinguish small variations.

We describe for the first time a significantly higher
CXCR4/CD26 ratio on naive T-helper lymphocytes of
HHT patients that have experienced at least one seri-
ous infectious event. The magnitude of this effect on
clinical risk will require confirmation by further stud-
ies and may not be as large as the effect of pulmonary
AVMs, the risk factor well described in HHT [2] and
confirmed here. Since CXCR4 and CD26 are function-
ally linked, it is logical to suspect a higher chemotaxis
of naive T-helper lymphocytes in HHT patients with
HSI. This can appear paradoxical in an immunodefi-
cient state, but such a phenomenon, extended to the
whole immune system, has a central role in the physi-
opathology of the WHIM syndrome [40]. In this dis-
ease, most of the infectious phenotype seems to be due
to the chemotactic dysfunction of the myeloid lineage,
but patients also exhibit a decrease of NK and naive
T lymphocytes [41]. However, the validity of a similar
paradoxical mechanism underlying HHT-related infec-
tion profile is not obvious, since WHIM syndrome is
due to a CXCR4 gain-of-function mutation, resulting
in prolonged retention of leukocytes in bone marrow
and, consequently, panleukopenia, whereas no evi-
dence of such behaviour is currently available for naive
T-helper lymphocytes in HHT patients. Of note, the
CD26 expression on T lymphocytes is regulated upon
activation in inflammatory contexts such as rheuma-
toid arthritis or allograft rejection [11, 42]. Therefore,
inflammation could also participate in the shift of the
CXCR4/26 ratio in HHT patients with a history of
severe infection, despite the significant time elapsed
between the last episode of infection and the time of
enrollment.

Our study suffered from several limitations. The first is
the low number of subjects, limiting the statistical analy-
ses. This fact is inherent to studies on rare diseases. Nev-
ertheless, the ability to identify pulmonary AVM as an
infectious risk in HHT allows us to think that our pop-
ulation size was large enough to spot clinically relevant
parameters. Another limitation comes from the absence
of data about the lymphocyte profiles prior to the infec-
tious episodes. We do not provide any proof that the
modified expressions of CXCR4 and CD26 are stable
over time, knowing that lymphocyte profiles have circa-
dian and seasonal variations [43–45]. Nevertheless, the
major lymphocyte subsets of a given individual have been
reported with a low level of variability over time [46–48].
The assessment of CXCR4 and CD26 expression is only
based on flow-cytometry data and should be confirmed
by other techniques (RNA quantification, for example).
Plasma levels of chemotactic agents (especially CXCL12)

and functional assessment of T lymphocyte chemotaxis
could have brought more interpretability in our results.
These investigations should be conducted in future stud-
ies on this topic, as well as a more detailed evaluation of
the Th1, Th2 and Th17 lymphocyte sub-populations.

Conclusions

We report several findings suggesting that HHT is asso-
ciated with an alteration of the CXCL12/CXCR4 chemo-
tactic axis of T-helper lymphocytes. Patients exhibit a
decrease of their total count in the blood correlated with
a decrease of CXCR4 MFI ratio, a decrease of CXCR4
and CD26 surface expressions and a higher CXCR4/
CD26 ratio on the naive subset in the group with a his-
tory of severe infection. As the CXCL12/CXCR4 chem-
otactic axis is important in many parts of the immune
system, it may contribute to the greater susceptibility to
infection observed in HHT.

Methods

Selection of participants and collection of baseline
characteristics

Patients and HC were recruited between January and
October 2012 in two French HHT centers (Montpellier
and Lyon). Subjects were excluded if they were under
18 years of age or had any active or recent (<3-month)
conditions known to alter the immune system (infection,
surgery, pregnancy, solid cancer or lymphoma, autoim-
mune disease, immunosuppressant or systemic corticos-
teroid therapy).

All patients included in the study fulfilled 3 or 4 of the
Curaçao criteria and had undergone genetic analysis.
A thoracic computed tomography scan and an echo-
graphic liver assessment were systematically proposed to
all patients, according to the French guidelines for HHT
diagnosis and treatment. Cerebral or gastrointestinal
tract investigations were proposed only according to the
clinical context, including symptoms, clinical signs and
personal or familial histories.

Patients with a scheduled routine visit in the HHT
centers were screened for inclusion during the medical
consultation. They were considered to have a HSI if the
infectious episode required at least two days of hospitali-
zation (appendicitis excluded). For each patient included
with at least one HSI, a HHT patient without any HSI
and a HC were included, respecting a matching in sex
and age (±2 years).

Data regarding HHT symptoms, complete medical
history, treatments and clinical status at the time of the
study were collected during the consultation. Concerning
pulmonary AVM, only those large enough to be consid-
ered for treatment were taken into account (usually with
a diameter of the feeding artery > 3 mm). Blood samples
were collected after the medical assessment. Standard bio-
logical measurements (blood cell count, C-reactive pro-
tein, ferritin, creatinine, immunoglobulins G-A-M) were
made in each center according to their usual procedures.

CXCR4 and CD26 surface expressions on lymphocytes subsets

The phenotypic characterization of lymphocyte subsets
was performed using whole blood and standard immu-
nofluorescence / flow cytometry technology. All the anal-
yses were performed on EDTA-collected blood samples,
in the department of immunology of the Saint Eloi Uni-
versity Hospital (Montpellier-France).

The following monoclonal antibodies were used for staining: CD3-Krome Orange, CD4-PC7, CD8-APC-Alexa Fluor 700, CD56-PC5.5, CD45RA-ECD, HLA-DR-Pacific Blue (Beckman-Coulter), CXCR4-APC and CD26-FITC (BD biosciences), IgG1-APC and IgG1-FITC (Beckman-Coulter).

Analyses were realized on whole blood. Erythrocyte lysis was realized with the Immunoprep solution on TQ-prep automat (Beckman-Coulter), after antibody fixation. Cells were analyzed by a Navios flow cytometer with the Kaluza software (Beckman Coulter).

The gating strategy is detailed in Additional file 2: Fig. S1. Total lymphocytes were identified based on morphological properties. T, T-helper, T-cytotoxic and natural killer (NK) lymphocytes were defined according to the following phenotypes: CD3+, CD3+ CD4+, CD3+ CD8+ and CD56+ CD3-. Naive T-helper and T-cytotoxic lymphocytes were defined as CD45RA+ CD4+ and CD45RA+ CD8+, respectively. CD4+ HLA-DR+ and CD8+ HLA-DR+ cells were considered as activated T-helper and T-cytotoxic lymphocytes.

The CXCR4 and CD26 expressions were measured on
each subset by calculating the ratio of their MFI to the
MFI of their isotype counterparts.

The B lymphocyte population was simply estimated by
subtracting T and NK numbers from the total lympho-
cytes count.

Statistical analysis

Clinical and biological characteristics are presented in
tables. Immunological results are presented in bar charts
with median and interquartile ranges or as individual val-
ues with Spearman r coefficient.

Considering the small size of the groups and the
need to standardize the analysis of all the experiments,
we only used non-parametric tests for quantitative
variables. Comparisons between groups were made
using the Mann–Whitney *U*-test (for two groups) or
the Kruskal–Wallis test (for three groups or more).
Correlations between variables were tested with the

Spearman's rank test. For categorical variables, the contingency tables were analyzed with the chi-squared test. All the univariate analyses were done with PRISM version 6.01 (GraphPad Software).

For the multivariate analysis, we used the website https://www.pvalue.io [49] to perform a linear regression. As the distribution of residuals did not follow a normal distribution, confidence intervals and p-values were calculated by bootstrap (1000 iterations).

A *p*-value < 0.05 was considered as statistically
significant.

Abbreviations

HHT: Hereditary hemorrhagic telangiectasia; NK lymphocytes: Natural killer lymphocytes; HSI: History of severe infection; HC: Healthy control; AVM: Arteriovenous malformation; MNCs: Mononuclear cells; IV: Intravenous; MFI: Mean fluorescence intensity.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13023-021-02139-y.

**Additional file 1. Table S1:** Multivariable linear regression aimed at explaining the T-helper count as outcome variable in the 36 HHT patients. The explanatory variables tested were: CXCR4 MFI on T-helper lymphocytes, age and requirement of IV treatment for iron-deficiency anemia. Due to non-linearity in CXCR4 MFI on T-helper lymphocytes, this variable was divided in two classes ( > 4.48 vs ≤ 4.48) for analysis.

**Additional file 2.** Gating strategy. (a) Total lymphocytes were selected in whole blood after erythrocyte lysis and staining, based on their morphological properties. Subpopulations of T lymphocytes and NK lymphocytes were determined based on the surface markers as follows: CD3+ for T cells, CD3+CD4+ for T-helper (CD45RA+ for naive, CD45RA- for memory and HLA-DR+ for activated), CD3+CD8+ for T-cytotoxic (CD45RA+ for naive, CD45RA- for memory and HLA-DR+ for activated), CD56+CD3- for NK. (b) CXCR4 and CD26 expression was assessed on T subpopulations by calculating the ratio of their mean fluorescence intensity (MFI) to the MFI of their isotype counterparts

Acknowledgements

Dr. Eugene Matthew Tan kindly did the English proofreading.

Authors' contributions

AG, TV, PP and SR conceived the study and analyzed data. SR and SDG pro-
vided samples. AG and PP performed the experiments. AG wrote the manu-
script. SR, TV, PP and SDG corrected the manuscript. All authors reviewed and
approved the manuscript.

Funding

This work was funded by the 2011 Shire-HGT grant for rare diseases in internal medicine. The article processing charges were funded by FAVA-Multi, a French health organization for rare vascular diseases.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from
the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The protocol was approved by our local Ethics Committee (Montpellier-Nimes
Institutional Reviewing Board, registration number: IRB 12/07-01). All subjects
gave a written informed consent in accordance with the Declaration of Helsinki.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare no competing interests.

**Author details**

¹CHU de Montpellier, Médecine interne et maladies multi-organiques de l'adulte, Hôpital Saint Eloi, Montpellier, France. ²CHU de Montpellier, Laboratoire d'immunologie, Hôpital Saint Eloi, Montpellier, France. ³Centre National de référence Maladie de Rendu-Osler, Service de génétique Hôpital Mère-Enfant, Hospices Civils de Lyon, Bron, France.

Received: 17 July 2021 Accepted: 28 November 2021

Published online: 14 December 2021

**References**

1. Dupuis-Girod S, Bailly S, Plauchu H. Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost JTH. 2010;8:1447–56.

2. Dupuis-Girod S, Giraud S, Decullier E, Lesca G, Cottin V, Faure F, et al. Hemorrhagic hereditary telangiectasia (Rendu-Osler disease) and infectious diseases: an underestimated association. Clin Infect Dis Off Publ Infect Dis Soc Am. 2007;44:841–5.

3. Mathis S, Dupuis-Girod S, Plauchu H, Giroud M, Barroso B, Ly KH, et al. Cerebral abscesses in hereditary haemorrhagic telangiectasia: a clinical and microbiological evaluation. Clin Neurol Neurosurg. 2012;114:235–40.

4. Cirulli A, Loria MP, Dambra P, Di Serio F, Ventura MT, Amati L, et al. Patients with hereditary hemorrhagic telangiectasia (HHT) exhibit a deficit of polymorphonuclear cell and monocyte oxidative burst and phagocytosis: a possible correlation with altered adaptive immune responsiveness in HHT. Curr Pharm Des. 2006;12:1209–15.

5. Droege F, Pylaeva E, Siakaeva E, Bordbari S, Spyra I, Thangavelu K, et al. Impaired release of neutrophil extracellular traps and anemia-associated T cell deficiency in hereditary hemorrhagic telangiectasia. J Clin Med. 2020;9:767.

6. Ojeda-Fernández L, Recio-Poveda L, Aristorena M, Lastres P, Blanco FJ, Sanz-Rodríguez F, et al. Mice lacking Endoglin in macrophages show an impaired immune response. PLOS Genet. 2016;12:e1005935.

7. Guilhem A, Malcus C, Clarivet B, Plauchu H, Dupuis-Girod S. Immunological abnormalities associated with hereditary haemorrhagic telangiectasia. J Intern Med. 2013;274:351–62.

8. Bai Z, Hayasaka H, Kobayashi M, Li W, Guo Z, Jang MH, et al. CXC chemokine ligand 12 promotes CCR7-dependent naïve T cell trafficking to lymph nodes and Peyer's patches. J Immunol Baltim Md. 1950;2009(182):1287–95.

9. Herrera C, Morimoto C, Blanco J, Mallol J, Arenzana F, Lluis C, et al. Comodulation of CXCR4 and CD26 in human lymphocytes. J Biol Chem. 2001;276:19532–9.

10. Ohnuma K, Inoue H, Uchiyama M, Yamochi T, Hosono O, Dang NH, et al. T-cell activation via CD26 and caveolin-1 in rheumatoid synovium. Mod Rheumatol. 2006;16:3–13.

11. Jungraithmayr W, Enz N. CD26: the emerging role of a costimulatory molecule in allograft rejection. Cell Mol Immunol. 2020;17:1208–9.

12. Young K, Conley B, Romero D, Tweedie E, O'Neill C, Pinz I, et al. BMP9 regulates endoglin-dependent chemokine responses in endothelial cells. Blood. 2012;120:4263–73.

13. Post S, Smits AM, van den Broek AJ, Sluijter JPG, Hoefer IE, Janssen BJ, et al. Impaired recruitment of HHT-1 mononuclear cells to the ischaemic heart is due to an altered CXCR4/CD26 balance. Cardiovasc Res. 2010;85:494–502.

14. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801–10.

15. Kawaguchi N, Zhang T-T, Nakanishi T. Involvement of CXCR4 in normal and abnormal development. Cells. 2019;8:185.

16. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10:858–64.

17. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion. Br J Cancer. 2009;101:983–91.

18. Busso N, Wagtmann N, Herling C, Chobaz-Pélat V, Bischof-Delloye A, So A, et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol. 2005;166:433–42.

19. Creery D, Weiss W, Lim WT, Aziz Z, Angel JB, Kumar A. Down-regulation of CXCR-4 and CCR-5 expression by interferon-gamma is associated with inhibition of chemotaxis and human immunodeficiency virus (HIV) replication but not HIV entry into human monocytes. Clin Exp Immunol. 2004;137:156–65.

20. Berezné A, Bono W, Guillevin L, Mouthon L. Diagnosis of lymphocytopenia. Presse Médicale Paris Fr. 1983;2006(35):895–902.

21. Vitiello L, Ferraro E, Simone SD, Gatta L, Feraco A, Racioppi L, et al. CXCL12 prolongs naïve CD4+ T lymphocytes survival via activation of PKA, CREB and Bcl2 and BclIX up-regulation. Int J Cardiol. 2016;224:206–12.

22. Phillips R, Ager A. Activation of pertussis toxin-sensitive CXCL12 (SDF-1) receptors mediates transendothelial migration of T lymphocytes across lymph node high endothelial cells. Eur J Immunol. 2002;32:837–47.

23. Cané S, Ponnappan S, Ponnappan U. Altered regulation of CXCR4 expression during aging contributes to increased CXCL12-dependent chemotactic migration of CD4+ T cells. Aging Cell. 2012;11:651–8.

24. Nakvasina MA, Popova LI, Lidokhova OV, Artyukhov VG. Modulation of structural and functional properties of human lymphocytes by reactive oxygen species. Bull Exp Biol Med. 2019;166:481–6.

25. Bowlus CL. The role of iron in T cell development and autoimmunity. Autoimmun Rev. 2003;2:73–8.

26. Boother EJ, Brownlow S, Tighe HC, Bamford KB, Jackson JE, Shovlin CL. Cerebral abscess associated with odontogenic bacteremias, hypoxemia, and iron loading in immunocompetent patients with right-to-left shunting through pulmonary arteriovenous malformations. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017;65:595–603.

27. Caulfield J, Fernandez M, Snetkov V, Lee T, Hawrylowicz C. CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells. Immunology. 2002;105:155–62.

28. Grujic M, Matic IZ, Crnogorac MD, Velickovic AD, Kolundzija B, Cordero OJ, et al. Activity and expression of dipeptidyl peptidase IV on peripheral blood mononuclear cells in patients with early steroid and disease modifying antirheumatic drugs naïve rheumatoid arthritis. Clin Chem Lab Med. 2017;55:73–81.

29. Scott-Algara D, Balabanian K, Chakrabarti LA, Mouthon L, Dromer F, Didier C, et al. Idiopathic CD4+ T-cell lymphocytopenia is associated with impaired membrane expression of the chemokine receptor CXCR4. Blood. 2010;115:3708–17.

30. Cotoia A, Cela O, Palumbo G, Altamura S, Marchese F, Mangialetto N, et al. High mobilization of CD133+/CD34+ cells expressing HIF-1α and SDF-1α in septic abdominal surgical patients. BMC Anesthesiol. 2020;20:158.

31. Skirecki T, Mikaszewska-Sokolewicz M, Godlewska M, Dolęgowska B, Czubak J, Hoser G, et al. Mobilization of stem and progenitor cells in septic shock patients. Sci Rep. 2019;9:3289.

32. Wetzel-Strong SE, Weinsheimer S, Nelson J, Pawlikowska L, Clark D, Starr MD, et al. Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations. Orphanet J Rare Dis. 2021;16:372.

33. Haribabu B, Richardson RM, Fisher I, Sozzani S, Peiper SC, Horuk R, et al. Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization. J Biol Chem. 1997;272:28726–31.

34. Kumar A, Humphreys TD, Kremer KN, Bramati PS, Bradfield L, Edgar CE, et al. CXCR4 physically associates with the T cell receptor to signal in T cells. Immunity. 2006;25:213–24.

35. Ramonell KM, Zhang W, Hadley A, Chen C, Fay KT, Lyons JD, et al. CXCR4 blockade decreases CD4+ T cell exhaustion and improves survival in a murine model of polymicrobial sepsis. PLOS ONE. 2017;12:e0188882.

36. Abbal C, Jourdan P, Hori T, Bousquet J, Yssel H, Pène J. TCR-mediated activation of allergen-specific CD45RO(+) memory T lymphocytes results in down-regulation of cell-surface CXCR4 expression and a strongly
reduced capacity to migrate in response to stromal cell-derived factor-1.
Int Immunol. 1999;11:1451-62.

37. Kobayashi N, Takata H, Yokota S, Takiguchi M. Down-regulation of CXCR4 expression on human CD8+ T cells during peripheral differentiation. Eur J Immunol. 2004;34:3370-8.

38. Noda M, Omatsu Y, Sugiyama T, Oishi S, Fujii N, Nagasawa T. CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice. Blood. 2011;117:451-8.

39. Madueño JA, Muñoz E, Blazquez V, Gonzalez R, Aparicio P, Peña J. The CD26 antigen is coupled to protein tyrosine phosphorylation and implicated in CD16-mediated lysis in natural killer cells. Scand J Immunol. 1993;37:425-9.

40. Gulino AV, Moratto D, Sozzani S, Cavadini P, Otero K, Tassone L, et al. Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood. 2004;104:444-52.

41. Majumdar S, Murphy PM. Adaptive immunodeficiency in WHIM syndrome. Int J Mol Sci. 2018;20:3.

42. Cordero OJ, Varela-Calviño R, López-González T, Calviño-Sampedro C, Viñuela JE, Mouriño C, et al. CD26 expression on T helper populations and sCD26 serum levels in patients with rheumatoid arthritis. PLOS ONE. 2015;10:e0131992.

43. Miyawaki T, Taga K, Nagaoki T, Seki H, Suzuki Y, Taniguchi N. Circadian changes of T lymphocyte subsets in human peripheral blood. Clin Exp Immunol. 1984;55:618-22.

44. Maes M, Stevens W, Scharpé S, Bosmans E, De Meyer F, D'Hondt P, et al. Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6, and soluble interleukin-2 and -6 receptor concentrations in normal volunteers. Experientia. 1994;50:821-9.

45. Lévi FA, Canon C, Touitou Y, Reinberg A, Mathé G. Seasonal modulation of the circadian time structure of circulating T and natural killer lymphocyte subsets from healthy subjects. J Clin Invest. 1988;81:407-13.

46. Tosato F, Bernardi D, Sanzari MC, Pantano G, Plebani M. Biological variability of lymphocyte subsets of human adults' blood. Clin Chim Acta Int J Clin Chem. 2013;424:159-63.

47. Sekiguchi DR, Smith SB, Sutter JA, Goodman NG, Propert K, Louzoun Y, et al. Circulating lymphocyte subsets in normal adults are variable and can be clustered into subgroups. Cytometry B Clin Cytom. 2011;80:291-9.

48. Backteman K, Ernerudh J. Biological and methodological variation of lymphocyte subsets in blood of human adults. J Immunol Methods. 2007;322:20-7.

49. Medistica. pvalue.io, a Graphic User Interface to the R statistical analysis software for scientific medical publications. 2020. https://www.pvalue.io.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

* fast, convenient online submission

* thorough peer review by experienced researchers in your field

* rapid publication on acceptance

* support for research data, including large and complex data types

* gold Open Access which fosters wider collaboration and increased citations

* maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

<figure><img src="image_7.png" /></figure>